Questcor (QCOR) is a biotechnology company focused on providing prescription drugs for central nervous system disorders. It offers ''Acthar'', the sole revenue driving drug, which treats patients with multiple sclerosis and infantile spasms. Acthar, in the first quarter of 2013, reported $126 million in revenue, compared to the company's total revenue of $135.1 million. This drug accounts to 93% of the total revenue. Its key areas of focus are neurology, nephrology, and rheumatology. The company makes research initiatives on a variety of medical conditions that are not completely controlled or cured with existing drugs on the market.
Acthar will bring additional upside on the revenue
Questcor's Acthar has received FDA approval for 19 separate indications in the U.S., only four of which are currently marketed. These four indications are Infantile Spasms, or IS, Multiple Sclerosis, or MS, Nephrotic Syndrome, or NS, and Rheumatology. The total sales for Acthar was $126 million in the first quarter of 2013, which decreased by 21% from the previous quarter. This decrease was due to change in the distribution channel and the introduction of a new reimbursement support center. The 9% quarter-over-quarter decline in new paid prescriptions to 1,750 in the first quarter of 2013 also contributed to Acthar's revenue decrease.
Best Heal Care Stocks For 2015: Koninklijke Philips NV (PHIA)
Koninklijke Philips NV, formerly Koninklijke Philips Electronics NV, is the Netherlands-based parent company of the Philips Group (Philips). The Company operates within three main business sectors, such as Healthcare, Consumer Lifestyle, and Lighting, as well as through the Innovation, Group & Services (IG&S) sector. The Healthcare sector offers both personal care and professional products, such as computer tomography equipment, radiography equipment and refurbished systems. Consumer Lifestyle sector offers a range of sound, vision, personal devices and household products, such as television, headphones, kitchen appliances, shavers and digital cameras, among others. Lighting sector offers lighting products, such as professional lamps, light-emitting diodes (LED), ballasts and luminaires, among others. The IG&S segment provides the operating sectors with support through shared service centers. It also includes projects which are not part of the operating sectors. Advisors' Opinion:- [By Corinne Gretler]
European stocks rose for a fourth day, extending a seven-week high, as companies from UBS AG to Royal Philips (PHIA) Electronics NV reported increased profit.
Hot Medical Stocks To Own Right Now: Impax Laboratories Inc.(IPXL)
Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. The company operates in two divisions, Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals division develops, manufactures, sells, and distributes generic pharmaceutical products. It provides its generic pharmaceutical prescription products directly to wholesalers and retail drug chains; and generic pharmaceutical over-the-counter and prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer?s disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson?s disease, and schizophrenia, as well as promotes third-party branded pharmaceutical products. As of May 2, 2011, the com pany marketed 101 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds; and another 16 of its generic pharmaceuticals representing dosage variations of 4 different pharmaceutical compounds. It markets and sells its generic pharmaceutical prescription drug products in the continental United States and the Commonwealth of Puerto Rico. The company has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V. Impax Laboratories, Inc. was founded in 1993 and is headquartered in Hayward, California.
Advisors' Opinion:- [By Eric Volkman]
Impax Laboratories (NASDAQ: IPXL ) �will soon hand out a raft of pink slips. As part of a move to slice costs, the company has announced a reduction in its headcount by roughly 110 employees. Most of these cuts will be effected at its manufacturing facility in Hayward, Calif.
- [By Max Macaluso, Ph.D.]
RLS hasn't been a high-priority target for the pharma industry given the lackluster sales of Requip and Horizant, a third competitor of�UCB's Neupro, and a number of generic alternatives. Impax Laboratories (NASDAQ: IPXL ) was one of the few developing a new therapy, called IPX159, but Impax put the kibosh on the drug after it failed to meet its primary endpoint in a phase 2b study. According to its latest quarterly report, Impax has no other RLS drugs in development and seems to be focusing on getting its rejected Parkinson's disease drug Rytary back to the FDA for a second chance at approval.
Hot Medical Stocks To Own Right Now: Vocera Communications Inc (VCRA)
Vocera Communications, Inc. (Vocera), incorporated on February 16, 2000, is a provider of mobile communication solutions. The Company�� solutions consist of its Voice Communication, Messaging and Care Transition solutions. Its Voice Communication solution, which includes a communication badge and a software platform, enables users to connect with other hospital staff. The Company�� Messaging solution delivers text messages and alerts directly to and from smartphones. Its Care Transition solution is a voice and text-based software application that captures, manages and monitors patient information when responsibility for the patient is transferred or handed-off from one caregiver to another, or when the patient is discharged from the hospital. Users can communicate with others using the Vocera communication badge or through Vocera Connect client applications available for BlackBerry, iPhone and Android smartphones, as well as Cisco wireless Internet protocol (IP) phones and other mobile devices. In January 2014, Vocera Communications Inc announced the acquisition of mVisum.
Communication solution can also be integrated with nurse call and other clinical systems to alert hospital workers to patient needs. The Company�� solutions are deployed in over 800 hospitals and healthcare facilities, including hospital systems, hospitals, and clinics, surgery centers and aged-care facilities. During the year ended December 31, 2011, the Company had shipped over 400,000 communication badges to its customers. The Company outsources the manufacturing of its products. Vocera offers a range of services, including clinical workflow design, wireless assessment, solution configuration, training and project management. It also provides a classroom-based curriculum for systems administrators, information technology professionals and clinical educators. The Company provides around-the-clock technical support to its customers through its support centers in San Jose, California, and Reading, United Kingdom.!
Voice Communication solution
The Company�� Voice Communication solution consists of a software platform that connects communication devices, including its hands-free, wearable, voice-controlled communication badges, Vocera-branded smartphones and third-party mobile devices that use its software applications to become part of the Vocera system. The system transforms the way mobile workers communicate by enabling them to connect with the right person simply by the name, function or group name of the person they want to reach, often while remaining at the point-of-care. Its system responds to over 100 voice commands.
Vocera�� Voice Communication solution is a software platform that runs on its customers��Windows-based servers. In addition, it controls the calling and messaging functions of the mobile client devices and maintains profiles for users and groups that enable customization of workflow patterns for each customer. The Company�� communication badge is a wearable device that operates over customers��wireless fidelity (Wi-Fi) networks. The badge is worn clipped to a shirt or on a lanyard. It can be used to conduct hands-free communication. It enables two-way voice conversations without the need to remember a phone number or use a handset. Its badge also incorporates automatic diagnostic mechanisms that feed data on wireless network performance back to the software platform for reporting and diagnosis of problems. In October 2011, it introduced the Vocera B3000 badge. In 2012, the Company added Cisco wireless IP phones to the list of mobile devices it supports.
Messaging solution
The Company�� Messaging solution delivers text messages, alerts and other information, directly to and from smartphones. Its solution consists of a software platform and client applications that run on BlackBerry, iPhone or Android devices. Its Messaging solution includes a range of client applications, including Alert, Chat and Commander.
Care! Transition Solution
The Company�� platform, which includes modules for patient transfers, shift changes, physician sign-outs and patient and family information exchanges, allows hospitals to standardize and monitor patient hand-offs. Its Care Transition solution can be deployed through either a hosted software-as-a-service model or as a server-on-site model and has been deployed by over 120 hospitals.
The Company competes with Cisco Systems, Ascom and Polycom.
Advisors' Opinion:- [By gurujx]
Vocera Communications Inc (VCRA) Reached the 3-year Low of $12.33
The prices of Vocera Communications Inc (VCRA) shares have declined to close to the 3-year low of $12.33, which is 64.4% off the 3-year high of $32.97.
- [By Evan Niu, CFA]
What: Shares of Vocera Communications (NYSE: VCRA ) have gotten slaughtered by 38% today after the company reported earnings.
So what: Revenue in the first quarter came in at $22.4 million, which translated into a non-GAAP net loss of $0.07 per share. Both figures were significantly worse than the $24.3 million in revenue and $0.02 per share adjusted loss that the Street was expecting. CEO Bob Zollars conceded that management was disappointed with the results.
- [By Victor Selva]
On Dec.24, Mario Gabelli, the Chairman and Chief Executive Officer of GAMCO Investors, Inc. added Communications Systems Inc. (JCS) at an average price of $11.05 and currently holds 330,172 shares of the stock. It was the 5th time he added the stock during this year, which makes me feel that he is betting in favor of a positive future for the consumption of network capacity.
Recommendations of the Board
Communications Systems is engaged in the manufacture and sale of modular connecting and wiring devices for voice and data communications, digital subscriber line filters, and structured wiring systems, and through its Transition Networks business unit in the manufacture of media and rate conversion products for telecommunications networks.
Few months ago the firm announced�a series of actions to increase revenues and improve profitability. The first change was to operate as a holding company, monitoring and supporting all the business units: Suttle, Transition Networks (TN) unit and JDL Technologies. With this ��ew format�� each unit will operate with a high degree of autonomy. This will result in the reduction of labor costs, the emphasizing of accountability in the units as well as better recognition of performance. "While difficult decisions for the Board, we believe the changes we have taken to restructure our parent company as a holding company and to focus on individual business unit performance is in the best interest of our shareholders and will increase shareholder value" said Curtis A. Sampson, the Company's Board Chair and Interim CEO. Furthermore, strategic investments in the TN unit such as marketing, sales and product development will boost revenues in the future.
Severe Warning Signs
Not all are good news, we found three severe warning signs issued by GuruFocus: Piotroski F-Score of 2 is low, which usually implies poor business operation; revenue has been in decline over the past 3 years and operating margin has been in 5-year
Hot Medical Stocks To Own Right Now: Tekmira Pharmaceuticals Corp (TKMR)
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc. Advisors' Opinion:- [By Ben Rooney]
Canadian biotech firm Tekmira Pharmaceuticals (TKMR)' stock surged in September after the FDA authorized the company's drug for patients with Ebola in the United States. Shares have since pulled back. The company has started limited production of its drug, TKM-Ebola, which will be available in early December.
- [By Lisa Levin]
Tekmira Pharmaceuticals (NASDAQ: TKMR) shares climbed 34.11% to $13.25. The volume of Tekmira Pharmaceuticals shares traded was 2187% higher than normal. Tekmira signed a development agreement with Monsanto (NYSE: MON) on delivery technology for agricultural applications.
- [By Matt Egan]
Tekmira Pharmaceuticals (TKMR) surged 19% on Wednesday, leaving it up a whopping 180% since mid-July. Investors are betting the Vancouver-based company has a leg up on competitors because last month the FDA gave it a green light to provide its experimental TKM-Ebola drug to test subjects with "confirmed or suspected Ebola virus infections."
No comments:
Post a Comment